09:54 AM EST - Trillium Therapeutics Inc. : Reported financial results for the three months ended March 31, 2019. As of March 31, 2019, Trillium had cash and cash equivalents and marketable securities, and working capital of $52.4 million and $42.3 million, respectively, compared to $45.4 million and $34.2 million, respectively at December 31, 2018. Net loss for the three months ended March 31, 2019 of $10.7 million was higher than the loss of $8.6 million for the three months ended March 31, 2018. Trillium Therapeutics Inc.
shares T.TRIL are trading up $0.01 at $0.80.